Speciality Medicines Limited IPO Set to Launch on March 20, 2026
Speciality Medicines Limited, a prominent player in the marketing and distribution of specialty pharmaceutical products across various therapeutic areas, has announced the opening of its Initial Public Offering (IPO) on Friday, March 20, 2026. Based in Mumbai, Maharashtra, the company aims to raise approximately ₹29.14 crore at the upper price band, with the shares slated for listing on the BSE SME platform. This move marks a significant step in the company's growth trajectory, leveraging public investment to fuel expansion and innovation.
IPO Details and Share Allocation
The issue comprises 23,50,000 equity shares, each with a face value of ₹10, offered within a price band of ₹117 to ₹124 per share. The allocation strategy is designed to cater to diverse investor segments:
- Qualified Institutional Buyers: Up to 21,000 equity shares
- Non-Institutional Investors: Up to 10,89,000 equity shares
- Retail Individual Investors: Up to 10,90,000 equity shares
- Market Maker: Up to 1,50,000 equity shares
The subscription window will remain open from March 20, 2026, to March 24, 2026, providing investors with a five-day period to participate in this offering.
Utilization of Proceeds and Strategic Goals
The net proceeds from the IPO are earmarked for several key initiatives aimed at bolstering the company's market position and operational capabilities. These include:
- Establishing a dedicated Research and Development (R&D) Centre to drive innovation in pharmaceutical solutions.
- Facilitating product registration and development for sale in international markets, enhancing global reach.
- Funding marketing and promotional activities to increase brand visibility and market penetration.
- Meeting working capital requirements to ensure smooth day-to-day operations.
- Supporting general corporate purposes for sustained growth and stability.
This strategic allocation underscores the company's commitment to expanding its footprint in high-value therapeutic areas such as oncology, immunology, and neurology.
Leadership Insights and Market Outlook
Mr. Parth Goyani, Chairman & Managing Director of Speciality Medicines Limited, emphasized the IPO's role in the company's evolution. "We have built Speciality Medicines Limited with a strong focus on providing access to high-value specialty pharmaceutical products across critical therapeutic areas. Over the years, our distribution strength, customer relationships, and product portfolio have enabled us to expand across more than 20 states in India and several international markets," he stated. "The proposed IPO marks an important milestone in our growth journey. The proceeds will primarily be utilized to establish a dedicated R&D center, strengthen product registrations in international markets, expand our marketing and promotional reach, and support working capital requirements. These initiatives will enable us to broaden our product portfolio, deepen our global footprint, and enhance our ability to deliver innovative solutions for complex chronic conditions."
Mr. Brijesh Parekh, Founder & Director of Unistone Capital Private Limited, the Book Running Lead Manager for the issue, expressed confidence in the company's prospects. "We are delighted to be associated with the proposed IPO of Speciality Medicines Limited and to support the company in this important milestone of its growth journey. The company has built a strong presence in the specialty pharmaceuticals segment with a diversified portfolio of products and a growing footprint across India and international markets. The company's focus on high-value therapeutic areas and its strong distribution network position it well to capture opportunities in the rapidly expanding specialty pharmaceutical market," he remarked. "The proceeds from the IPO will support the establishment of a dedicated R&D center, expansion of product registrations in international markets, strengthening of marketing initiatives, and funding of working capital requirements. We believe these initiatives will further enhance the company's growth prospects and help it scale its operations in both domestic and global markets."
The Registrar to the Issue is Skyline Financial Services Private Limited, ensuring a smooth and compliant process for investors. As the IPO unfolds, it represents a pivotal moment for Speciality Medicines Limited, poised to leverage public capital for sustainable long-term growth in the competitive pharmaceutical industry.
